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A B S T R A C T
Background: Interleukin 6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) are biomarkers of systemic low-
grade inflammation (SLI) in depression and anxiety. The question if SLI in those conditions is related to comorbid
chronic medical conditions has not been resolved. DSM-5 Somatic symptom disorders and related disorders
(SSRD) are conditions with serious distress related to physical symptoms as main criterion. They can occur in
patients with medically unexplained symptoms (MUS) and in patients with known comorbid chronic medical
conditions. Often, comorbid depression and anxiety are present. SSRDs offer the opportunity to explore the role of
SLI in relation to mental distress, including trauma, MUS, chronic medical conditions and comorbid mental
disorder. AIM: We hypothesized that increased IL-6 and hsCRP may be directly linked to SLI in SSRD, and that
comorbid chronic medical conditions, childhood trauma, current stress and comorbid depression and anxiety may
be risk factors that account for some of the variance of SLI in SSRD. METHODS: We explored these relationships in
a large sample of 241 consecutive outpatients with SSRD. RESULTS: Mean hsCRP level was 3.66 mg/l, and mean
IL-6 level was 3.58 pg/ml. IL-6 and hsCRP levels were associated with each other: τ ¼ 0.249, p < .001; a medium
size correlation. Comorbid chronic medical conditions, adverse childhood events other than sexual trauma, and
current stress levels were not associated with IL-6 or hsCRP levels. CONCLUSION: IL-6 and hsCRP are elevated in
SSRD, indicating SLI in SSRD independently of comorbid chronic medical conditions. In clinical research, elevated
IL-6 and hsCRP can be used as biomarkers of SLI and can indicate risk for childhood sexual abuse in SSRD.
Elevated hsCRP may be a biomarker indicating risk for comorbid depression or high pain levels in SSRD as well.
1. Introduction
Research concerning Systemic Low-grade Inflammation (SLI) in mental
disorders is gaining ground (Miller et al., 2003; Rief et al., 2010). Pro-
longed SLI activity, resulting in sickness behaviour (fatigue, pain, mood
and cognitive symptoms), may provokemental disorders (Viljoen, Pantzer,
2005) such as depression (Dantzer et al., 2008; Del Grande da Silva et al.,
2016; Simon et al., 2008), Post Traumatic Stress Disorders (PTSD)
(Lindqvist et al., 2017) and anxiety disorders (Del Grande da Silva et al.,
2016; Kovacs et al., 2016; Vogelzangs et al., 2016). Associations with cy-
tokines such as interleukin-6 (IL-6) have been explored mostly in depres-
sive disorder (Dowlati et al., 2010; Simon et al., 2008) with inconsistent
results (Einvik et al., 2012) which might be explained by possible con-
founding by comorbid chronic medical conditions such as cardiovascular
disorders (Howren et al., 2009). IL-6 plays a role in both innate and
adaptive immunity (Scheller et al., 2011). Within the adaptive immune
response, IL-6 plays a crucial role in activating antibody-producing B cells
to proliferate, leading to an enhanced antibody response. Concentrations
of IL-6 are elevated in patients with acute and severe infection (Tsalik et al.,
2012) but also in chronic inflammatory disorders such as rheumatoid
arthritis and inflammatory bowel disease (Gabay, 2006). Normal concen-
trations of IL-6 range between 2 and 10 pg/ml. Although IL-6 levels in the
normal range do not exclude the possibility of an ongoing inflammatory
process such as SLI, it is unclear what might be an indicative IL-6 level for
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SLI in mental disorders.
As part of the innate immune system, IL-6 acts on hepatocytes to
induce expression of C-reactive protein (CRP), in what is known as the
acute phase response. Depending on lab procedures, normal values for
CRP range between 2 and 10 mg/l, and a level of 10 mg or higher is an
indicator of a serious infection, trauma or inflammatory condition. (Mayo
Clinic, 2020) However, despite a level of <10 being in the normal range,
epidemiological and intervention studies found a level of 3–10 mg/l on
minor CRP elevation, defined as high-sensitivity CRP (hsCRP), to be
prospectively associated with an increased cardiovascular risk (Pfützner,
Forst, 2006). A level of 3.0 mg/l or higher is considered to indicate at
least in part an inflammatory process, or SLI (Ridker, 2016).
Adverse childhood experiences (ACE) occur in mental disorders such
as depressive and anxiety disorders (Van der Feltz-Cornelis et al., 2019).
Cytokine levels in depressive disorder may differ between depressed
patients who experienced ACE and patients who did not; (Pedrotti
Moreira et al., 2018); however, the literature is ambiguous (Grosse,
2016) (Pasco et al., 2010; Powers et al., 2019) as another study found
that an association between ACE and hsCRP in depressed individuals
disappeared after controlling for socioeconomic factors and health be-
haviours (Gouin et al., 2017). A meta-analysis revealed an association
between CRP but not IL-6 with childhood trauma with larger effect sizes
for clinical samples with chronic medical conditions such as cancer
compared to general population samples (Baumeister et al., 2016). Based
upon the literature, whether current or childhood traumatization is
associated with IL-6 and hsCRP and what role chronic medical conditions
might play in this link, remains unclear. A group of mental disorders that
may be of particular interest for exploring the questions above are So-
matic Symptom and Related Disorders (SSRD). They are characterized by
physical symptoms that are associated with significant distress and
impairment (American Psychiatric Association, 2013). SSRD are a group
of conditions that include Somatic Symptom Disorders (SSD), SSD with
pain, conversion disorder/functional neurological disorder (CD/FND),
and health anxiety and can occur in patients with known chronic medical
conditions as well as in patients with medically unexplained symptoms
(MUS).
We hypothesize that increased IL-6 and hsCRP may indicate SLI in
SSRD, and that comorbid chronic medical conditions, trauma and stress,
and comorbid depression and anxiety may be risk factors that account for
some of the variance in SLI in SSRD.
Our objectives are to:
1 Describe IL-6 and hsCRP levels and clinical characteristics in patients
with SSRD in relation to comorbid chronic medical conditions; ACE,
AAE, childhood and adult sexual abuse; current stressful life events
(LCU); and comorbid mental disorders
2. Explore if IL-6 and hsCRP levels are associated with each other.
Explore which one is better to use as biomarker for SLI in SSRD in
clinical research. Explore if there is scope to establish cut-off scores
for use as a biomarker for SLI in SSRD in clinical research.
2. Methods
This is a cross-sectional observational study. The study sample con-
tains patients with comorbid medical conditions, and patients without
comorbid medical conditions. Also, it contains patients with trauma and
stress, and patients without, as well as patients with and without co-
morbid depression and anxiety. This diversity in the sample enables us to
evaluate our hypothesis. The Scientific Institutional Review Board of GGz
Breburg approved the study protocol.
Consecutive outpatients diagnosed with SSRD at the Clinical Centre
of Excellence for SSRD (CLGG), Tilburg, the Netherlands, from
September 2016 until September 2018 were eligible after diagnosis at
intake. Patients were excluded if they were <18 years old, did not
complete any questionnaires during intake, had IQ< 80 or had substance
dependency.
The standard intake procedure has been described elsewhere (Van
Eck van der Sluijs et al., 2017) and is summarized below. Medical ex-
amination by a physician involved assessment of somatic symptoms by
medical history taking; a questionnaire measuring somatic symptoms;
physical examination; neurological examination; laboratory assessments;
venipuncture according to a biochemical, haematological and immuno-
logical lab protocol, including the measurement of hsCRP and IL-6
(ELISA). Immunological lab was taken if physical examination did not
suggest an active transient infection. Standardised lab procedures for
hsCRP and for IL-6, authorised by the Expert Committee on Biological
Standardization (ECBS) of the World Health Organization (WHO), are
available (Gaines Das, Poole, 1993; Whicher, 1998). labs. In this study,
plasma levels of IL-6 were measured by high sensitivity enzyme linked
immunosorbent assay (ELISA; Quantikine HS ELISA R&D systems
HS600B) performed by DS2, Dynex Elisa robot automated analyzers.
Intra assay precision CV% was in the interval 6.9–7.8; interassay preci-
sion CV% was in the interval 6.5–9.6. The detection range of this assay
was 0.02–10 pg/ml. None of the respondents had IL-6 levels below the
detection limit of 0.02 pg/ml and 4 had values above the reference value
of 10 pg/ml, as delineated in the outlier analysis. For hsCRP, immuno-
turbidimetry by automated analyzers was performed. The declared
detection limit was 0.20 mg/l. Specimens were drawn from participants
and frozen at 80 C until thawed for assay.
Psychiatric evaluation including exploration of sexual trauma was
performed by semi-structured interview to provide SSRD DSM-5 classi-
fication and other comorbid DSM-5 classifications (American Psychiatric
Association, 2013). Psycho-diagnostic questionnaire assessment of psy-
chological symptoms, ACE, AAE, and stressful life events were performed
by questionnaires and Mini-International Neuropsychiatric Interview
(MINI) (Sheehan et al., 1998). Patient files and the data-warehouse were
assessed for the variables described in Table 1.
Supervision and checks by two supervisors (JvE and CFC) secured the
standardization of the intake procedure, the reporting in the electronic
patient files, and the data extraction and data-entry by trained assistants.
2.1. Statistical analysis
Variables explored were IL-6 and hsCRP, SSRD categories, pain, so-
matic symptoms and functioning. Elevated hsCRP was defined by a level
of 3 mg/L or higher. Elevated IL-6 was established as described in the
methods. Covariates were ACE, childhood sexual abuse, current daily life
stress measured as Holmes and Rahe life events score (LCU), current
trauma measured by AAE, as well as comorbid chronic medical condi-
tions, comorbid mental disorders, age, gender, and marital status.
Regarding the description of clinical characteristics, for the contin-
uous variables, means, SD, medians and range were calculated. For the
categorical variables, frequencies and percentages were calculated. This
was done for all participants together and for each SSRD category sepa-
rately. Whether IL-6, hsCRP and clinical characteristics differed between
SSRD categories (Table 2) and between patients with and without co-
morbid chronic medical conditions (Table 3) was explored with a robust
one-way ANOVA (SSRD categories) or the non-parametric Wilcoxon-
Mann-Whitney test (comorbid chronic medical conditions) if the variable
was continuous, and with a chi-square test if the variable was categorical,
and p-values reported. To test whether IL-6 and hsCRP levels were
associated with any of the clinical characteristics, Kendall’s correlation
test was performed. Kendall’s τ is a non-parametric correlation and was
chosen because of the skewed distribution of IL-6 and hsCRP in the
sample. For categorical characteristics, such as gender and comorbidity,
Kendall’s τ is similar to Wilcoxon-Mann-Whitney test, a non-parametric
variant of the independent t-test (Table 4). We used non-parametric
tests to take into account the skewed distribution of IL-6 and hsCRP
values and the presence of outliers. We performed a sensitivity analysis to
deal with outliers for IL-6 and hsCRP values as follows. First, we per-
formed log transformation of IL-6 and hsCRP and all IL-6 and hsCRP
values of > 3SD above the mean were taken out of the sample. Then, the
C.M. van der Feltz-Cornelis et al. Brain, Behavior, & Immunity - Health 9 (2020) 100176
2
associations between IL-6 and hsCRP and the characteristics in Tables 2
and 3 were recalculated. If any differences were found in the statistical
conclusions, this was reported in the Tables. A regression coefficient for
age and IL-6 was obtained by a robust regression analysis to take viola-
tions of the normality assumption into account. A chi-square test was
used to explore sexual revictimization in patients reporting childhood
sexual abuse. We explored if IL-6 and hsCRP levels (continuous) were
associated using a Kendalls τ correlation. A sensitivity analysis was
performed by excluding the outliers.
In order to establish cut-off scores for use in clinical research as a
biomarker for SLI in SSRD, several steps were undertaken. As first step, a
score of 3.0 mg/l or higher was used as a cut-off score for elevated hsCRP,
assuming that a hsCRP score of 3.0 mg/l or higher is an indicator of
inflammation(Ridker, 2016). We then checked which IL-6 value corre-
sponded with the percentage of patients having 3.0 mg/l or higher for
hsCRP in our sample, a method used elsewhere (Cho et al., 2013). As a
second step, we took out all outlying values of IL-6 and performed a
regression analysis with hsCRP as the predictor and IL-6 levels as the
dependent variable to explore which IL-6 value corresponds to a hsCRP
level of 3.0 mg/l. We then explored if elevated levels of hsCRP and of
IL-6, as established by the method described above, were associated with
particular clinical characteristics for which they could be used as
biomarker, by comparing patient with and without elevated IL-6 levels
(Table 5) and patient with and without elevated hsCRP levels (Table 6).
Means, median, SD and range are given for the continuous variables and
frequencies and percentages for the categorical variables. The
non-parametric Wilcoxon-Mann-Whitney test was used to test whether
patients with and without elevated levels differed significantly on these
variables if the variable was continuous, and with a chi-square test if the
Table 1
Data sources/measurement.
Factors Classification Based on
Diagnostic classification





Yes/No Patient file: DSM
classification (if unclear, also
MINI) (Sheehan et al., 1998)
Personality
disorder
Yes/No Patient file: DSM
classification and SCID-2
(Spitzer et al., 1990)
Anxiety disorder Yes/No Patient file: DSM




Yes/No Patient file: DSM




Yes/No Patient file: DSM
classification (if unclear, also
MINI)
Comorbid CMC Yes/No Patient file: DSM




Relationship status Single/Living together or
Married/Living apart
together/Other








Single with children/With a
partner without children/
With a partner with children




Social safety net Good (both contact with
friends and family)/
Moderate (only a single
family member or a single
friend)/Bad (no friends/
family)




Education level Very low (prim. school)/
Low (junior high school)/
Medium (High school
2,3,4)/High (bachelor)/
Very high (MSc, PG)















Yes Patient file: ACE (Anda et al.,
1998), intake and Psychiatric
evaluation. The ACE
International Questionnaire
(ACE-IQ) is developed by the
WHO. Development has been
ongoing and for this study, the
available version in 2015 was
used. This covers mostly ACE
indicating family dysfunction,
physical, sexual and
emotional abuse and neglect
by parents or caregivers. It
was translated from English to
Dutch and back-translated to
provide the official Dutch
version.(van der





Yes/No Patient file: AAE, LCU






Yes/No Patient file: ACE, intake and
Psychiatric evaluation
Adult sexual abuse Yes/No
Table 1 (continued )
Factors Classification Based on
Patient file: AAE, intake and
Psychiatric evaluation
Symptoms at intake
Scores: Physical symptoms were measured using the PSQ51 (Van
Hemert, 2003), which is a 51-item questionnaire. The total
score on the PSQ ranges from 0 to 51 and represents the
number of physical symptoms that were regularly or often
present in the last week. Higher scores indicated a higher
symptom burden. De Waal provided normative data.(De Waal
et al., 2004) They were also measured by the PHQ15.(Kroenke
et al., 2002) Higher scores indicated a higher symptom burden.
Depression was assessed using the PHQ-9. The PHQ-9 is a
reliable 9-item self-report questionnaire, with higher scores
indicating higher levels of depressive symptoms (Kroenke
et al., 2009). Item scores ranged from 0 (not at all) to 3 (nearly
every day), and total scores ranged from 0 to 27. Cut-off points
of 5, 10, 15, and 20 represent mild, moderate, moderately
severe and severe levels of depression.(Kroenke et al., 2010)
Anxiety was assessed using the GAD-7. The GAD-7 is a reliable
7-item self-report questionnaire that measures symptoms of
anxiety during the last 2 weeks. Higher scores indicated a
higher symptom burden. GAD-7 scores range from 0 to 21, and
cut-off scores of 5, 10, and 15 represent mild, moderate and
severe levels of anxiety.(Spitzer et al., 2006)
We used the SF-36 general health domain score to assess
general functioning. Studies confirmed the SF-36’s validity and
reliability.(Ware and Sherbourne, 1992) The SF-36 is a
self-report questionnaire that contains 36 items, which are
distributed across eight scales. Scores range from 0 to 100,
where higher scores indicate better general functioning. It was
validated in the US and in the Netherlands.(Ware et al., 1994;
Aaronson et al., 1998) It is responsive to change.(McHorney
et al., 1993) Normative data are available.(Garrat et al., 1994)
Chronic non-malignant pain was measured by the Brief Pain









Venepuncture Biochemical, Haematological and immunological lab protocol
including hsCRP (immunoturbidimetry) and ELISA for IL-6
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Table 2
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p-value for variable differences between the SSRD categories
















































variable was categorical. We dealt with missing data by using pairwise
deletion.
3. Results
Table 2 shows the clinical and demographic characteristics and p-
values for the sample as a whole and for the different SSRD
classifications.
The mean level of IL-6 in the total sample was 3.58 (16.03) with
median 1.65 pg/ml and range 0.62–226. Seventy-two (35%) of the pa-
tients had elevated IL-6. After outlier removal (4 IL-6 values), mean IL-6
level was 2.12 (1.4) pg/ml, median remained the same, 1.65 pg/ml, and
the range was 0.62–9.65 pg/ml. Mean hsCRP level was 3.66 (4.54) mg/l;
median 2.17, range 0.2–31.14.37.5% of the patients have an hsCRP level
higher than 3.0 mg/l. No outliers in hsCRP level were detected. There
were no significantly different levels of IL-6 or hsCRP, prevalence of
comorbid chronic medical conditions, or ACE in the different SSRD
classifications. However, adult traumatic experiences (AAE) occurred in
over 60% of all SSRD categories, except illness anxiety, which had
significantly less AAE (28.6%; p ¼ .004). Childhood sexual abuse
occurred in only 7.1% of patients with illness anxiety, but significantly
more often in SSD with pain (36.1%) and with CD/FND (42.9%) (p ¼
.015). Expectedly, high pain score (BPI) occurred significantly more often
in SSD with pain. Regarding sexual revictimization, childhood sexual
abuse was reported in 53 (22.2%) of the sample. In patients with child-
hood sexual abuse, 21.4% reported adult sexual abuse versus 4.6% in
patients without childhood sexual abuse (χ2 (1) ¼ 12.427, p ¼ .001, phi
¼ .252).
Table 3 shows the clinical and demographic characteristics of the
sample divided as SSRD with comorbid chronic medical conditions
versus without comorbid chronic medical conditions.
There were no significant differences in terms of IL-6 or hsCRP levels
between patients with versus those without comorbid chronic medical
conditions. The only significant differences concerned age (p < .0001)
and perceived general health (p ¼ .002). Patients with chronic medical
conditions were on average six years older, with an average of 44.8 years
compared to 38.7 (13.12) in the group without comorbid chronic med-
ical conditions. The SF36 general health score was significantly higher in
the patients with comorbid chronic medical conditions, with a score of
19.27 (3.45) versus 18.15 (3.01) in the patients with SSRD with unex-
plained medical symptoms.
Table 4 shows the associations between IL-6 and hsCRP levels
(continuous) and clinical variables over the whole sample.
IL-6 was associated with age, but hsCRP was not. Robust regression
analysis yielded a Beta of .022 (95%CI¼ 0.012–0.032), meaning that for
every year of an increase in age, there was a predicted increase in IL-6 of
0.022 pg/ml. IL-6 and hsCRP were both associated with pain. hsCRP was
associated with the number of somatic symptoms (PSQ51 and PHQ15)
and was negatively associated with a comorbid autism spectrum
disorder.
IL-6 and hsCRP levels (continuous) were associated (Kendall’s τ ¼
0.223, p < .001). After the exclusion of the four outliers, the association
between IL-6 and hsCRP levels (continuous) was Kendall’s τ ¼ 0.249, p
< .001.
An IL-6 value of 2.01 pg/ml corresponded with the percentage of
patients with a hsCRP level of 3.0 mg/l or higher. As the second step,
assuming that a hsCRP of 3.0 mg/l or higher is an elevated hsCRP level
(Ridker, 2016), and after removing the outliers, we found that a hsCRP
level of 3 mg/l predicted an IL-6 level of 2.056 pg/ml in a regression
analysis (95%CI around prediction: 1.864–2.249).
We then explored if levels of hsCRP 3.0 mg/l and IL-6  2.056 pg/
ml were associated with particular clinical characteristics for which they
Table 3
Clinical characteristics in SSRD patients with comorbid CMC versus no comorbid CMC.
Comorbid CMC N ¼ 142 No Comorbid CMC N ¼ 99 p-value
Variable N M(SD) Median Range N (%) Variable N M(SD) Median Range N (%)
IL-6 2.4 (2.47) 0.62–19.4 Elevated* IL-6 5.33 (25.07) 0.82–226 Elevated* 0.842
123 1.64 43 (35%) 83 1.77 29 (34.9%)
IL-6 with outliers removed 2.14 (1.43) 0.62–8.46 41 (33.9%) IL-6 with outliers removed 2.08 (1.36) 0.82–9.65 27 0.758
121 1.63 81 1.76 (33.3%)
hsCRP 3.81 (4.91) 0.2–31.14 49 (36.3%) hsCRP 3.45 (3.97) 0.2–22.11 38 (39.2%) 0.784
135 2.22 97 1.99
Age 44.8 (13.12) 18–80 NA Age 38.73 (13.12) 15–78 NA < 0.001
142 44 99 35
Gender NA NA 58 (40.8%) Gender
99
NA NA 39 (39.4%) 0.821
142
Male N (%)
LCU 96.09 (103.07) 0–545 NA LCU 87.31 (78.02) 0–374 NA 0.993
116 67.5 85 72
PHQ9 14.33 (6.21) 0–27 NA PHQ9 14.24 (6.04) 0–27 NA 0.866
135 14 92 14
GAD7 11.4 (5.54) 0–21 NA GAD7 11.9 (5.17) 1–21 NA 0.567
136 11 94 11
BPI 5.84 (2.45) 0–10 121 (87.7%) BPI 5.36 (2.58) 0–10 74 (82.2%) 0.116
138 6.5 90 6
PSQ51 17.02 (9.28) 1–45 NA PSQ51 15.37 (8.35) 0–42 NA 0.186
136 17 93 14
PHQ15 15.51 (5.59) 5–28 NA PHQ15 15.54 (5.57) 0–30 NA 0.958
137 15 93 15
SF36 19.27 (3.45) 8–25 NA SF36 18.15 (3.01) 6–24 NA 0.002
140 20 94 18
Childhood Sexual Abuse NA NA 34 (23.9%) Childhood sexual abuse NA NA 19 (19.6%) 0.426
142 97
Adult sexual Abuse NA NA 8 (7.1%) Adult sexual abuse 82 NA NA 8 (9.8) 0.501
113
ACE 1.6 (1.88) 0–8 85 (61.2%) ACE 1.98 (2.36) 0–10 59 (62.8%) 0.379
139 1 94 1
AAE 1.35 (1.6) 0–7 82 (59%) AAE 1.64 (1.88) 0–8 58 (61.7%) 0.335
139 1 94 1
* Elevated IL-6 score ¼ score 2.056 or higher as indicated in results section 4.4.
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could be used as biomarkers. A sensitivity analysis removing the IL-6
outliers was performed and the p-values for differences between
elevated and non-elevated IL-6 levels are shown in Table 5.
Patients with elevated IL-6, i.e. levels of 2.056 pg/ml or higher, had
significantly higher hsCRP: 4.87 (5.2) mg/l in the elevated IL-6 group
versus 2.88 (3.86) mg/l in the non-elevated IL-6 group (p < .001). The
mean age was 47.14 (11.5) in the elevated IL6 group versus 39.68
(13.61) in the non-elevated IL6 group, a difference of 8 years (p < .001).
The elevated IL-6 group also showed significantly higher somatic
symptom levels (PSQ51mean 18.81 (9.09) versus 15.55 (8.85), p¼ .016.
Findings for hsCRP after sensitivity analysis with reported means and
SDs of IL-6 without the outlying IL-6 values are presented in Table 6.
Patients with elevated hsCRP, i.e. a level of 3.0 mg/l or higher, had
significantly higher IL-6 (2.52 (1.59) pg/ml) versus 1.89 (1.26) pg/ml in
the non-elevated hsCRP group (p < .001). They scored (marginal)
significantly higher on BPI (6.3 (2.24) versus 5.18 (2.59), p ¼ .002) and
on somatic symptoms (PSQ51 mean 18.27 (9.69) versus 15.38 (8.29), p
¼ .038; PHQ15 mean 16.7 (5.63) versus 14.94 (5.41), p ¼ 0.038).
Elevated hsCRP was significantly associated with childhood sexual
abuse: 31% of 87 patients with elevated hsCRP had a history of childhood
sexual abuse, versus 18.1% with non-elevated hsCRP (p ¼ .042).
4. Discussion
This study for the first time investigates IL-6 and hsCRP in a large
sample of patients with SSRD and demonstrates high levels indicating
SLI. It shows that IL-6 and hsCRP do not differentiate between SSRD
subclassifications such as SSD with pain, CD/FND and illness anxiety.
Also, its innovative design and abundance of data allows for establishing
that comorbid chronic medical conditions, general adverse childhood
events, and current stress are not associated with IL-6 and hsCRP levels.
We suggest that in clinical research, elevated IL-6 and hsCRP ca be used
as biomarkers for SLI and can indicate risk for childhood sexual abuse in
SSRD. Elevated hsCRP may also indicate risk for comorbid depression or
high pain levels in SSRD. We establish cut-off scores for the first time that
may be used in future clinical research.
The results show a mean IL-6 level of 3.58 (16.03) pg/ml and with
correction for outliers this is 2.12 (1.4) pg/ml. hsCRP mean is 3.66 (4.54)
mg/l, which is above the cut-off recommended by the American Heart
Association for increased risk of cardiovascular events and SLI. The mean
IL-6 level is higher than the cut-off of 2.056 pg/ml predicted by a hsCRP of
3.0 mg/l in our study. These levels are higher than in a study in the
Swedish general population (Garvin et al., 2016), higher than in a general
population study inManhattan (Luna et al., 2014) andmuch higher than in
an elderly general population sample in rural Iowa although the mean age
in the elderly sample is higher than in our study (Harris et al., 1999). Also,
the median of IL-6 and hsCRP in our study is higher than the median in a
UK study in civil servants in London (Cho et al., 2013). The high levels of
hsCRP and IL-6 in our sample fit a clinical population rather than a general
population sample and seem to be indicative of SLI in SSRD.
In this sample of patients with SSRD, 142 (58.9%) of the patients had
Table 4
Associations between IL6 and hsCRP and comorbid CMCs, ACE and recent stress,
and other clinical variables.
Variable IL-6 hsCRP
Age τ ¼ :26, z ¼ 5:53, p < :001 τ ¼ :04, z ¼ 0:91
p ¼ :364
Gender τ ¼ :00, z ¼  0:03, p ¼ :
978
τ ¼  :05, z ¼  1:00, p ¼
:317
LCU τ ¼  :07, z ¼  1:38, p ¼
:168
τ ¼ :06, z ¼ 1:20, p ¼ :232
SSRDcat p ¼ 0.419 p ¼ 0.579
Somatic τ ¼ :01, z ¼ 0:20, p ¼ :
841
τ ¼ :01, z ¼ 0:28, p ¼ :783
PHQ9 τ ¼ :09, z ¼ 1:91, p ¼ :
056
τ ¼ :07, z ¼ 1:47, p ¼ :143
GAD7 τ ¼ :03, z ¼ 0:65, p ¼ :
514
τ ¼ :04, z ¼ 0:80, p ¼ :425
BPI τ ¼ :11, z ¼ 2:13, p ¼ :033 τ ¼ :14, z ¼ 2:87, p ¼ :004
PSQ51 τ ¼ :08, z ¼ 1:64, p ¼ :
102
τ ¼ :12, z ¼ 2:54, p ¼ :011
PHQ15 τ ¼ :04, z ¼ 0:88, p ¼ :
379
τ ¼ :11, z ¼ 2:46, p ¼ :014
SF36 τ ¼ :04, z ¼ 0:76, p ¼ :
449
τ ¼ :05, z ¼ 1:04, p ¼ :299
Childhood Sexual
Trauma
τ ¼ :08, z ¼ 1:45, p ¼ :
146
τ ¼ :09, z ¼ 1:72, p ¼ :085
Adult sexual trauma τ ¼ :08, z ¼ 1:20, p ¼ :
232
τ ¼  :07, z ¼  1:21, p ¼
:224
ACE τ ¼ :05, z ¼ 0:90, p ¼ :
370
τ ¼ :05, z ¼ 1:09, p ¼ :277
AAE τ ¼ :05, z ¼ 0:90, p ¼ :
370
τ ¼ :01, z ¼ 0:26, p ¼ :792
Co_Dep τ ¼ :02, z ¼ 0:28, p ¼ :
780
τ ¼ :06, z ¼ 1:03, p ¼ :305
Co_GenAnx τ ¼  :03, z ¼  0:55, p ¼
:581
τ ¼  :04, z ¼  0:78, p ¼
:437
Co_PanDis τ ¼  :04, z ¼  0:72, p ¼
:474
τ ¼  :02, z ¼  0:44, p ¼
:656
Co_PTSS τ ¼ :05, z ¼ 0:82, p ¼ :
414
τ ¼ :05, z ¼ 0:84, p ¼ :401
Co_PersDis τ ¼  :01, z ¼  0:17, p ¼
:869
τ ¼  :06, z ¼  1:14, p ¼
:254
Co_ADHD τ ¼  :03, z ¼  0:46, p ¼
:647
τ ¼  :06, z ¼  1:20, p ¼
:228
Co_Aut τ ¼  :06, z ¼  1:03, p ¼
:303
τ ¼ :14, z ¼ 2:68, p ¼
:007
Co_OCD τ ¼  :06, z ¼  1:04, p ¼
:297
τ ¼ :05, z ¼ 0:91, p ¼ :365
Co_Anx_comb* τ ¼  :02, z ¼  0:27, p ¼
:788
τ ¼ :01, z ¼ 0:20, p ¼ :839
* General Anxiety disorder, Panic Disorder, PTSS, and/or OCD as comorbidity.
Table 5
Clinical characteristics in elevated IL-6 compared to not elevated IL-6 after sensitivity analysis.
Variable High IL-6 N (%) N Low IL-6 N (%) N p value
hsCRP 4.87 (5.2); 2.86; [0.2–31.14] 34 (48.6%) 70 2.88 (3.86); 1.24; [0.2–23.41] 37 (28.2%) 131 <0.001
Age 47.14 (11.5); 47; [19–78] NA 72 39.68 (13.61); 38; [15–78] NA 134 <0.001
Gender NA 28 (38.9%) 72 NA 55 (41%) 134 0.764
LCU 85.52 (91.12); 65.5; [0–501] NA 58 96.95 (95.52); 78; [0–545] NA 116 0.415
Somatic comorbidity NA 43 (59.7%) 72 NA 80 (59.7%) 134 0.998
PHQ9 15.53 (6.45); 16; [0–27] NA 70 13.74 (6.04); 14; [0–27] NA 126 0.058
GAD7 12.3 (5.49); 13; [1–21] NA 70 11.34 (5.31); 11; [1–21] NA 128 0.220
BPI 6.11 (2.23); 6; [0–10] 64 (91.4%) 70 5.5 (2.54); 6; [0–10] 107 (84.3%) 127 0.146
PSQ51 18.81 (9.09); 17; [4–45] NA 69 15.55 (8.85); 15; [0–36] NA 128 0.016
PHQ15 16.29 (5.28); 16; [5–27] NA 68 15.35 (5.81); 15; [0–30] NA 130 0.236
SF36 19.41 (3.04); 20; [13–25] NA 71 18.57 (3.47); 19; [6–25] NA 129 0.170
Childhood Sexual_Trauma NA 22 (30.6%) 72 NA 24 (18.2%) 132 0.112
Adult sexual Trauma NA 8 (13.6%) 59 NA 8 (7.8%) 103 0.234
ACE 2.23 (2.38); 1; [0–9] 49 (70%) 70 1.57 (1.91); 1; [0–10] 79 (60.8%) 130 0.064
AAE 1.87 (2.12); 1; [0–8] 45 (64.3%) 70 1.35 (1.5); 1; [0–6] 80 (61.5%) 130 0.230
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comorbid chronic medical conditions. There were no significant differ-
ences between SSRD classifications or patients with and without co-
morbid chronic medical conditions in terms of IL-6 or hsCRP levels. This
suggests that SLI, which is not related to comorbid chronic medical
conditions, may be an underlying mechanism, and that IL-6 and hsCRP
are indicators of a direct pathophysiologic mechanism related to SLI in
SSRD. The finding that both IL-6 and hsCRP are not associated with co-
morbid chronic medical conditions suggest that both are biomarkers
reflecting SLI in SSRD.
All SSRD classifications showed a mean pain level above the cut-off
score of 3 for clinically relevant pain on the BPI (Brecht et al., 2007),
ranging between 4.31 in Illness Anxiety and 7.25 in SSD with pain. The
mean IL-6 level in SSD with pain in our sample is approximately twice as
high than in a sample of fibromyalgia patients (Mendieta et al., 2016). As
the association between IL-6 and level of pain that we found cannot be
explained by comorbid chronic medical conditions, a logical explanation
might be that pain is a cytokine-related effect, as our findings suggest a
role of SLI in the pathogenesis of nonspecific pain in SSRD. This is in line
with a number of studies suggesting IL-6 plays a role in pain disorders,
including fibromyalgia (Andres-Rodríguez et al., 2019; Uçeyler et al.,
2011). The pathophysiological role of cytokines in fibromyalgia is still
unclear. One mechanism might be that IL-6 sensitizes pain receptors,
although that would be at the cellular level and would not concern IL-6 in
the circulation (Atzeni et al., 2019). Other studies suggest that prolonged
sickness behaviour could be the underlying mechanism in the association
between hsCRP, pain and depression. Also, It could be that pain and sleep
disturbance are mediators of increased inflammatory activity, rather than
pain being a consequence of increased inflammatory activity(Allen et al.,
2020; Haack et al., 2007; Quartana et al., 2015). Unfortunately, we do
not have data on sleep patterns to explore that in this dataset.
The average ACE score is 1.75, and 61.8% of the patients report ACE,
which is almost similar to the 64% reported in the original ACE field
study amongst 17,000 people visiting a medical evaluation centre in the
USA. (Desai et al., 2002) However, the ACE scores in our study are lower
than the 77% prevalence of ACE reported in specialty mental health
outpatients with anxiety and depressive disorders (van der Feltz-Cornelis
et al., 2019a).
Childhood sexual abuse was reported in 22.2% of the whole sample.
We found high AAE levels and high rates of childhood sexual abuse,
especially in SSD with pain and in CD/FND. Childhood sexual abuse was
associated with adult sexual abuse in 21.4% of cases; therefore, sexual
revictimization occurred in one in 5 cases of childhood sexual abuse. This
rate is lower than in Australian community studies reporting approxi-
mately 35% revictimization (Werner et al., 2016), and in a study in
specialty mental health outpatients with anxiety and depressive disorder
in the Netherlands reporting 42% sexual revictimization (van der
Feltz-Cornelis et al., 2019a). Therefore, the question arises whether there
might be a particular mechanism that sparks the development of SLI and
CD/FND after experiencing childhood sexual abuse and whether that
involves sexual revictimization.
Both elevated hsCRP and elevated IL-6 are associated with childhood
sexual abuse. Childhood sexual abuse contributes to psychological
trauma and its consequences. Maybe sexual abuse in a child would be
associated with physical injury and the deposit of body material or other
substances in the body of the child, and hypothetically this might induce
immunological reactions that might have effects into adulthood. How-
ever, this has so far not been explored. We found that sexual revictim-
ization occurs in 1 in 5 patients with childhood sexual abuse in this
sample; however, the analysis showed no association between hsCRP and
adult sexual abuse, so that would not be an explanation. Baumeister et al.
found elevated IL-6 and hsCRP in childhood trauma (2016) and proposed
that somatic comorbidity or comorbid depression or different kinds of
trauma might play a role in this. However, we did not find an association
with general childhood trauma other than sexual trauma, and not with
comorbid chronic medical conditions. Also, although mean levels of
anxiety are at the clinical level in our sample, the association between
hsCRP (p¼ .029) or IL-6 (p¼ .066) and childhood sexual abuse remained
significant after controlling for PTSD or GAD7. Hence our study does not
support a role for anxiety or comorbid PTSD as explanation of elevated
hsCRP or IL-6 in case of childhood sexual abuse by anxiety or comorbid
PTSD in SSRD. Cellular pathways may be involved. T cell expression has
been found to be elevated in women with PTSD who experienced
childhood sexual abuse independently of norepinephrine or cortisol
levels (Lemieux et al., 2008). Future research should explore this path-
ogenic mechanism further. IL-6 and hsCRP were associated with each
other with a medium effect size. This leaves room for other mechanisms
affecting their association. There may be several possible explanations
for this. Research suggests that, although hsCRP is associated with IL-6
and can predict cardiovascular risk (Koenig et al., 1999), being an
acute phase protein produced in the liver after activation by IL-6 (Vola-
nakis, 2001), it might not be the most eligible biomarker for chronic SLI,
whereas IL-6 plays a role in both acute phase and chronic inflammatory
processes, as well as in autoimmunity, via various pathways (Tanaka
et al., 2014). Another explanation might be that IL-6 and hsCRP might be
biomarkers for SLI in slightly different patient profiles. Although the
underlying mechanism needs to be elucidated further, this study suggests
that elevated IL-6 and hsCRP can be used as biomarkers for SLI in SSRD
independently of comorbid chronic medical conditions. They can also
indicate risk for childhood sexual abuse in SSRD and elevated hsCRP can
indicate risk for comorbid depression or high pain levels in SSRD as well.
Both hsCRP and IL-6 have been identified as reliable biomarkers for
inflammation, indicating different parts of the inflammation pathway, by
the Centers for Disease Control and Prevention and the American Heart
Association (Pearson et al., 2003), in a scientific statement in which they
Table 6
Clinical characteristics elevated hsCRP versus non-elevated hsCRP after removal of IL-6 outliers.
Variable High hsCRP N percentage N Low hsCRP Low Percentage N p value
IL6_outliers removed 2.52 (1.59); 1.98; [0.7–9.65] 33 (47.1%) 70 1.89 (1.26); 1.48; [0.62–8.46] 33 (26%) 127 < 0.001
Age 41.31 (13.28); 41; [18–72] NA 87 42.67 (13.27); 41; [15–78] NA 145 0.563
Gender NA 33 Male (37.9%) 87 NA 57 (39.3%) 145 0.835
LCU 102.04 (95.63); 80; [0–545] NA 72 87.8 (93.76); 64.5; [0–501] NA 122 0.132
Somatic comorbidity NA 49 (56.3%) 87 NA 86 (59.3%) 145 0.655
PHQ9 15.23 (5.74); 15; [4–27] NA 83 13.7 (6.16); 13; [0–27] NA 135 0.030
GAD7 12.28 (5.27); 13; [0–21] NA 82 11.23 (5.38); 11; [1–21] NA 139 0.141
BPI 6.3 (2.24); 7; [0–10] 77 elevated BPI(92.8%) 83 5.18 (2.59); 5; [0–10] 110 (80.3%) 137 0.002
PSQ51 18.27 (9.69); 16; [1–45] NA 81 15.38 (8.29); 15; [0–36] NA 140 0.038
PHQ15 16.7 (5.63); 18; [5–30] NA 83 14.94 (5.41); 14; [0–27] NA 139 0.038
SF36 19.33 (3.2); 19.5; [10–25] NA 84 18.47 (3.34); 19; [6–25] NA 142 0.066
Childhood
Sexual_Trauma NA 27 (31%) 87 NA 26 (18.1%) 144 0.042
ACE 2.08 (2.35); 1; [0–9] 52 (62.7%) 83 1.64 (1.93); 1; [0–10] 91 (64.1%) 142 0.356
AAE 1.57 (1.88); 1; [0–8] 49 (59%) 83 1.46 (1.65); 1; [0–7] 88 (62%) 142 0.974
Co_Aut NA 2 (2.3%) 87 NA 13 (9%) 145 0.116
C.M. van der Feltz-Cornelis et al. Brain, Behavior, & Immunity - Health 9 (2020) 100176
7
guided the possibilities and pitfalls of clinical use as biomarkers. They
also indicated which would be useful for use as cardiovascular clinical
risk biomarker, and which for other conditions. In terms of cut-off levels,
based upon the results, we found an IL-6 level of 2.056 pg/ml corre-
sponding with a hsCRP level of 3.0 mg/l. To take lab variety into account,
we suggest using a cut-off for IL-6 of 2.0 pg/ml. This would enable us to
conduct future research applying and validating those cut-offs for
profiling studies. (van der Feltz-Cornelis, 2020).
4.1. Strengths and limitations
This is an innovative study which attempted to approach the question
of SLI in SSRD in a clinical sample and to explore clinical relevance and
possible diagnostic value of IL-6 and hsCRP. The sample size was large
and the wealth of systematically assessed clinical data enabled us to
explore the influence of demographic and clinical characteristics,
including several aspects of trauma and stress, as well as somatic and
psychiatric comorbidity on the association between IL-6, hsCRP and
several SSRD categories. We shed light on the extent to which SLI might
play a role in SSD, SSD with pain, CD/FND and illness anxiety, and this
opens avenues for further research. The finding that IL-6 and hsCRP
levels were associated with pain and somatic symptoms but were not
associated with comorbid chronic medical conditions is of high clinical
relevance. The finding that hsCRP and IL-6 are associated with childhood
sexual abuse in SSRD indicates the possibility to use both to discern a
patient profile combining SLI and childhood sexual abuse in SSRD.
Elevated hsCRP also seems to discern pain and comorbid depression
states with SLI in SSRD. Furthermore, we were able to suggest a cut-off
level for IL-6 to be used as a biomarker in SSRD, something that so far
has not been done, that can be validated in further research, and that
opens the avenue of conducting clinical profiling studies. All of these can
be considered strengths of our study. There are, however, also limita-
tions. The cross-sectional, observational design does not allow control-
ling for confounders for which data are not available, as could be done in
an experimental randomised controlled design. Smoking (Zevin et al.,
2001) and obesity (Yudkin et al., 1999) are known to be of influence on
SLI, but we had no data on these variables available in this sample. Our
study sample provides the opportunity to make an intragroup compari-
son only, as we cannot compare with healthy controls from the same
region. The latter would be relevant in terms of generalisability of our
findings, as there might be uncontrollable associations with local envi-
ronmental factors, including water, food, pollution, and climate condi-
tions, that might play a role in cytokine levels in a given population.
Other limitations are that some of the SSRD types had rather small
numbers of patients. Also, this is a sample of patients with longstanding
SSRD symptoms who visited a clinical centre of excellence that provides
treatment to the 5% most complex patients in the Netherlands (Van Eck
van der Sluijs et al., 2017). Hence, this study provides us with knowledge
about the levels of SLI and the use of IL-6 and hsCRP as clinical bio-
markers in chronic long-term cases of SSRD; this cannot automatically be
generalized to SSRD in general.
4.2. Recommendations for research
Longitudinal studies are needed that explore a possible temporal as-
sociation between IL-6 or hsCRP, pain levels, childhood sexual abuse and
treatment outcome in SSRD. This program of research should enable us to
describe patient profiles (van der Feltz-Cornelis, 2020) that may benefit
from different treatment provisions for SSRD, taking clinical character-
istics and biomarkers into account. To this end, a personalised medicine
approach for SSRD might be developed.
5. Conclusion
IL-6 and hsCRP levels are substantially higher in SSRD compared to
the general population and to fibromyalgia patients. IL-6 and hsCRP
indicate SLI in SSRD independently of comorbid chronic medical con-
ditions. In terms of cut-off levels, based upon the results, we found an IL-6
level of 2.056 pg/ml corresponding with a hsCRP level of 3.0 mg/l. In
clinical research, elevated IL-6 and hsCRP can be used as biomarkers for
SLI and can indicate risk for childhood sexual abuse in SSRD. Elevated
hsCRP may also be used as a biomarker indicating risk for comorbid
depression or high pain levels in SSRD. Further high-quality longitudinal
studies are needed to confirm these findings and to evaluate the
magnitude of these associations.
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